Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPM 226
Discontinued Product
PM 226 (Cat. No. 6220) has been withdrawn from sale for commercial reasons.
Description: Potent and selective CB2 receptor agonist; BBB permeable; neuroprotective
Chemical Name: 7-(1,1-Dimethylheptyl)-9-methoxy-4,4-dimethyl-4H-[1]benzopyrano[3,4-d]isoxazole
Purity: ≥98% (HPLC)
Biological Activity for PM 226
PM 226 is a potent and selective CB2 receptor agonist (Ki = 12.8 nM; EC50 = 38.67 nM). Exhibits negligible affinity for the CB1 receptor (Ki > 40,000 nM) and no activity at the GPR55. Suppresses neuroinflammation by reducing microglial activation in a multiple sclerosis mouse model. BBB permeable; anti-inflammatory and neuroprotective.
Technical Data for PM 226
| M. Wt | 357.49 |
| Formula | C22H31NO3 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1949726-13-9 |
| PubChem ID | 132510986 |
| InChI Key | VFWIRWAAMNBBFG-UHFFFAOYSA-N |
| Smiles | CCCCCCC(C)(C1=CC(OC)=C2C3=C(C(C)(OC2=C1)C)C=NO3)C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for PM 226
References for PM 226
References are publications that support the biological activity of the product.
Navarro et al (2016) Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front. Neurosci. 10 406 PMID: 27679556
Morales et al (2016) Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J.Med.Chem. 59 6753 PMID: 27309150
Gómez-Cañas et al (2016) Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol.Res. 110 205 PMID: 27013280
View Related Products by Target
View Related Products by Product Action
Keywords: PM 226, PM 226 supplier, PM226, Potent, selective, CB2, agonists, agonism, BBB, permeable, anti-inflammatory, neuroprotective, cannabinoids, receptors, Receptors, 6220, Tocris Bioscience
Citations for PM 226
Citations are publications that use Tocris products.
Currently there are no citations for PM 226.
Reviews for PM 226
There are currently no reviews for this product. Be the first to review PM 226 and earn rewards!
Have you used PM 226?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GPCR Product Listing
A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:
- Rhodopsin-like Receptors
- Glutamate Receptors
- Frizzled Receptors
- GPCR Signaling
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Pain Research Product Guide
A collection of over 280 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Cannabinoid Receptor Ligands Scientific Review
Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.